


## Amredobresib

<b>Cat. No.:</b>	HY-145550
<b>CAS No.:</b>	1610044-98-8
<b>Molecular Formula:</b>	C <sub>26</sub> H <sub>29</sub> N <sub>9</sub>
<b>Molecular Weight:</b>	467.57
<b>Target:</b>	Epigenetic Reader Domain
<b>Pathway:</b>	Epigenetics
<b>Storage:</b>	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 0.5 mg/mL (1.07 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.1387 mL	10.6936 mL	21.3872 mL
5 mM	---	---	---
10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Amredobresib is a potent inhibitor of BET. Amredobresib inhibits the binding of bromodomains to acetylated lysines on histone H3 and H4 and thus acts as important regulators of gene transcription. Amredobresib is useful for the research of acute myeloid leukemia (AML) and cancer (extracted from patent WO2019145410A1 and WO2021175824A1)<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

BET<sup>[1]</sup>

### REFERENCES

[1]. Ulrike Tontsch-Grunt, et al. Combination treatment of acute myeloid leukemia. Patent WO2019145410A1.

[2]. Shaonan Wang, et al. Method for administration of an anti cancer agent. Patent WO2021175824A1.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA